• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

News

Insmed announces reverse stock split

Biopharmaceutical company Insmed Incorporated has announced that its shareholders have approved a one-for-ten reverse stock split and the conversion of its Series B preferred stock into common stock. Insmed acquired Transave and its Arikace inhaled liposomal amikacin in December 2010. The company is developing Arikace for the treatment of Pseudomonas aeruginosa … [Read more...] about Insmed announces reverse stock split

Shareholder opposes CPEX merger

Mangrove Partners, which holds approximately %5.7 of the outstanding shares of CPEX Pharmaceuticals, has announced that it will oppose the merger of CPEX with FCB, a wholly-owned subsidiary of Footstar Corporation. The merger was announced in early January 2011. According to Mangrove, the $27.25 per share offer for CPEX, which is developing Nasulin intranasal insulin, … [Read more...] about Shareholder opposes CPEX merger

Pearl Therapeutics announces new President and CEO

Chuck Bramlage has been appointed President and Chief Executive Officer of Pearl Therapeutics, replacing interim President and CEO Howard Rosen. Pearl, a California pharmaceutical company developing inhaled treatments for COPD and asthma, was founded in 2006. Its lead product, PT 003, a LAMA/LABA combination MDI, is moving into Phase 2b trials. Bramlage was most … [Read more...] about Pearl Therapeutics announces new President and CEO

Pharmaxis begins marketing Aridol challenge test in US

Australian company Pharmaxis is launching its Aridol inhaled dry powder mannitol bronchial challenge test in the US. The FDA approved the product in October 2010 for the assessment of bronchial hyperresponsiveness in patients 6 years old or older. Aridol is already marketed in many European countries, Australia, and Korea. According to Pharmaxis, the Aridol … [Read more...] about Pharmaxis begins marketing Aridol challenge test in US

Asthma and Allergy Foundation of America names “asthma capitals”

The Asthma and Allergy Foundation of America (AAFA) has published its annual list of US "asthma capitals," led this year by Richmond, Virginia. The list ranks 100 metropolitan areas in terms of difficulties that they present for asthma patients living in the area. Criteria for ranking the list include factors such as the prevalence of asthma in the area, the … [Read more...] about Asthma and Allergy Foundation of America names “asthma capitals”

Positive results for Verona lead candidate

A dosage trial of Verona Pharma's inhaled mixed phosphodiesterase (PDE) 3/4 inhibitor RPL554 for the treatment of mild asthma has demonstrated positive bronchodilation without any significant adverse effects at dosages two and four times higher than had been tested in a previous safety study. Verona is looking to license the drug or to find a partner for continued … [Read more...] about Positive results for Verona lead candidate

Vectura announces better than expected financial results

Since October 1, 2010, Vectura's financial performance has exceeded the board's expectations, according to the company's interim management statement. Chief Executive Chris Blackwell attributes the improved performance to a restructured R&D program and says that Vectura expects to have more than £73m cash on hand by March 31, 2010. Read the company's press … [Read more...] about Vectura announces better than expected financial results

MAP Pharmaceuticals appoints new board chair

Scott R. Ward has been named Chairman of the Board of Directors by MAP Pharmaceuticals, replacing Staven A. Elms. MAP plans to submit an NDA for its Levadex inhaled ergotamine for the treatment of migraine headaches within the next few months. Read the company's press release. … [Read more...] about MAP Pharmaceuticals appoints new board chair

Inspire drops respiratory drug program after failure of CF drug

North Carolina specialty pharma company Inspire Pharmaceuticals has announced that it is cutting 27% of its workforce (65 jobs) after its denufosol inhalation solution for the treatment of cystic fibrosis failed a Phase 3 trial. The company says that it will drop pulmonary drug development altogether in order to focus on its opthalmic products. Read the company's … [Read more...] about Inspire drops respiratory drug program after failure of CF drug

Activaero gets €5 million in new funding

A group of investors led by LSP Life Sciences Partners of Amsterdam has put together €5 million that device company Activaero will use for continued development of its inhalation systems. Activaero recently initiated clinical studies involving the delivery of inhaled corticosteroids (ICS) using its Akita Jet nebulizer system. Read the company's press release. … [Read more...] about Activaero gets €5 million in new funding

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 404
  • Page 405
  • Page 406
  • Page 407
  • Page 408
  • Interim pages omitted …
  • Page 417
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews